All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ISB 1442, a first-in-class anti-CD38/anti-CD47 bispecific antibody, for the treatment of relapsed/refractory (R/R) multiple myeloma (MM).1
ISB 1442 is a biparatopic bispecific antibody with two binding arms to target CD38 and CD47. The CD47 and signal-regulatory protein alpha (SIRPα) interaction is blocked by the anti-CD47 arm, whilst the anti-CD38 arm drives binding with tumor cells and through avidity-induced binding can further block adjacent CD47 receptors. ISB 1442 has an engineered fragment crystallizable region to increase antibody-dependent cell cytotoxicity, antibody-dependent cell phagocytosis, and complement-dependent cytotoxicity. The structure and mechanism of action of ISB 1442 are outlined in Figure 1.
Figure 1. Mechanism of action of ISB 1442 mediated phagocytosis of tumor cells*
FcyRs, Fc receptors for IgG; SIRPα, signal regulatory protein α.
*Adapted from Jiang.2 Created with BioRender.com.
In comparison with daratumumab, an anti-CD38 monoclonal antibody, ISB 1442 demonstrated increased antitumor potency in both high and low-CD38-expressing tumors. ISB 1442 showed increased on-target tumor impacts as well as no detectable red blood cell depletion in vitro compared with magrolimab in preclinical trials.
An open-label, first-in-human, multicenter phase I/II study (NCT05427812) will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of ISB 1442 for R/R MM.3 Eligibility criteria include patients with R/R MM who have been treated with a CD38 antibody and have relapsed to three or more prior lines of therapy in the US.3
In this phase I trial, patients will be treated at escalating doses of ISB 1442 to establish its safety profile based on predetermined treatment-related adverse events.2 The phase II part of the trial, or dose expansion, will operate in two arms: the first being patients with three prior lines of therapy, including anti-CD38, and the second being patients who have received T cell-redirected therapies.2 The phase II primary endpoint is overall response rate. Secondary endpoints include progression-free survival, overall survival, duration of response, pharmacokinetics, and immunogenicity.2
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox